ERBB3 and ductal breast carcinoma in situ: However estimates vary, with one study reporting overexpression of HER3 in 67% of comedo ductal carcinoma in situ (DCIS), 52% of invasive ductal carcinomas, 71% of mixed in situ/invasive carcinomas and 25% of invasive lobular carcinomas [42].